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Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice with an increasing incidence and prevalence. [1] With ageing, the risk of thromboembolic and hemorrhagic events increases dramatically. As it has been reported previously, 3-year survival rate among patients with AF over 75 years of age after stroke is less than 50%, and almost 90% of those patients will remain disabled. [2] Anticoagulant therapy administration, even in elderly patients, can significantly improve the survival rate in this group, primarily by reducing the risk of ischemic stroke. [3] Inability of an adequate international normalized ratio (INR) control, severe renal failure, drug intolerance and risk of bleeding are the most common reasons preventing the use of anticoagulants. [4] It is believed that most of these restrictions are conditional, and some of them can be neglected. Yet, frailty remains one of the most powerful independent factors influencing the anticoagulation therapy in elderly patients. [5] Patients with severe frailty were often excluded from large randomized trials because of the difficulties in performing follow-up visits, thus resulting in the lack of evidence for the efficacy and safety of oral anticoagulant therapy in elderly population. This group of patients is most susceptible to trauma, is more likely to suffer from dementia, and they are more likely to be disabled. Often, a physician is simply not sure that the patient will return for a follow-up visit for further status assessment and dosage adjustment, which is most relevant while taking vitamin K antagonists. Either way, elderly patients are among the most difficult group of reference, because they have the shortest life expectancy and reduced quality of life. All these cir-*Correspondence to: doctordavtyan@mail.ru cumstances force clinicians to look for alternatives to oral anticoagulation therapy. Left atrial appendage (LAA) is a well-known source of thromboembolism in AF. LAA percutaneous closure is an effective and safe method of nonpharmacological prevention of thromboembolic complications in patients with AF. Moreover, it reduces the drug load of the patient. [6] Nowadays, LAA endovascular closure has become the only alternative to anticoagulant treatment. The analysis of available reports of large-scale studies and registry data on LAA closure safety and efficacy clearly shows intraoperative complications' reduction as the result of procedure technique improvement. [7] [8] [9] [10] [11] On the other hand, there is a lack of data on LAA occlusion procedure safety in elderly patient population. Clinical characteristics and comorbid status of patients, enrolled in large randomized trials, assessing the comparative efficacy and safety of LAA closure with oral anticoagulants (OACs, vitamin K antagonists), typically differs from those in the elderly population. [6] We performed a single-centre, retrospective observational study. From 2012 to 2016, LAA endovascular occlusion was performed in 72 patients for prevention of ischemic stroke. The indications for LAA closure were: non-tolerance of OACs (42 patients), recurrent bleedings (30 patients). Patients were divided in two groups according to age: ≤ 75 years [group 1, n = 54 (75%)] and >75 years [group 2, n = 18 (25%)]. Baseline clinical and demographic characteristics of patients are present in Table 1 . All patients underwent preprocedural contrast-enhanced CT of the left atrium (LA) and pulmonary veins. The LAA occluder implantation procedure was performed under fluoroscopy and transesophageal echocardiography (TEE) guidance, a single transseptal puncture was performed and LAA angiography was carried out. Occlusion device type and size, and a delivery system were chosen according to the integrated information from CT angiography, TEE and fluoroscopy. In 38 patients, the Amplatzer Cardiac Plug (ACP) occluder was used, and in 34 patients the Watchman device (WD) occluder was selected. In both groups, antithrombotic therapy was continued for a period of 3 to 6 months after the procedure. At follow-up visits (45 days, 3 months and 12 months) control TEE was performed. After 12 months further monitoring was carried out remotely. The total follow-up period was 164.9 patient-years. Statistical analysis was performed using Statistica 10.0 for Windows (StatSoft Inc., USA). Continuous variables were present as mean ± SD. Comparisons between two groups were performed by two-sided Student t test and two-sided Fisher's exact test, as appropriate. Kaplan-Meier analysis was performed to estimate survival over time. A P value ≤ 0.05 was considered to be significant. Successful LAA occluder implantation was performed in all patients (100%). There was no significant difference in a mean procedural time (68.23 ± 17.34 min vs. 67.8 ± 19.9 min, P = 0.622) between age groups, nor in a mean contrast media volume used (116.2 ± 31.52 mL vs. 124.25 ± 24.16 mL, P = 0.732) and hospital stay time (7.6 ± 2.1 days vs. 7.8 ± 1.6 days, P = 0.324) ( Table 2 ). In group 1, one procedure-related death occurred the next day (1.85% retroperitoneal fatal bleeding). There were no other procedure-and device-related complications, including cardiac tamponade, ischemic stroke, device dislodgement/migration. During the follow-up period, there were no cerebral and other embolic events (Figure 1) .
At first follow-up visit (45 days), silent thrombus formation on the atrial surface of the device was detected by TEE Total number of complications 1 (1.85%) 0 P = 1.000
Mean hospital stay, days 7.6 ± 2.1 7.8 ± 1.6 P = 0.324
Data are expressed as mean ± SD. ACP: Amplatzer cardiac plug; WD:
Watchman device. There are no significant differences in procedural data and complication rates between groups. No thromboembolic events were detected in our study.
in two cases (one patient from each group). In both cases, thrombus resolved on LMWH therapy (within 21 days) without any sequelae. At further follow-up visits (3 months and 1 year), there was no other evidence of LA thrombosis. Oral anticoagulation therapy was discontinued after 3-6 months in all patients. Additionally, antiplatelet therapy was also ceased in five patients. During the follow-up, five patients died in both groups, with no significant difference in the overall mortality between the groups (Figure 2 , 0.056 vs. 0.112; P = 0.434).
The major finding of our study is that LAA closure device implantation procedure success and complication rates do not differ between elderly patients aged more than 75 years compared to younger patients. Moreover, there was no significant difference in all-cause mortality between both groups during the follow-up period.
Our results correlate with the data from the study by Freixa, et al., [12] showing that endovascular LAA occlusion procedure in elderly patients is safe and not associated with an increased cardiovascular mortality, during mean follow-up of 16.5 months, in comparison with a younger cohort. [12] In our case series, there were no cardiovascular events in the elderly group despite an expected high stroke rate according to CHA 2 DS 2 VASc score without OACs (Figure 1 ). Considering that patients in both groups were not suitable for lifelong anticoagulation therapy, and had high thromboembolic and hemorrhagic risks, the expected benefit of LAA occlusion strategy for life prognosis seems to be very high.
In conclusion, percutaneous LAA closure is efficient and safe in elderly patients with high thromboembolic and hemorrhagic risks. However, this study was a retrospective analysis of procedures performed by one experienced operator, and the study results should be interpreted in the light of these limitations. Another limitation is the small number of patient included.
